Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 18, 2022

Clinical and Biomarker Results of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in TNBC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT)
J. Clin. Oncol 2022 Jun 01;40(16_suppl)513, P Sharma, SR Stecklein, R Yoder, et al

Further Reading